<br>        Inclusion Criteria:<br><br>          -  Subject has provided written informed consent before any study specific test or<br>             procedure and is willing and able to comply with the required follow-up visits and<br>             procedures<br><br>          -  Subject has a chronic, symptomatic lower limb ischemia defined as Rutherford<br>             categories 2 to 4<br><br>        Angiographic criteria:<br><br>          -  Single lesion or consecutive single lesions with a healthy segment(s) of = 2cm<br>             in-between<br><br>          -  De novo, restenotic or (re)occluded lesion(s) post Percutaneous Transluminal<br>             Angioplasty in the native superficial femoral artery (SFA) and or the proximal<br>             popliteal artery (PPA)<br><br>          -  Lesion(s) must be located at least 1 cm distal to the profunda femoris artery and at<br>             least 3 cm above the knee joint (radiographic joint space)<br><br>          -  Degree of stenosis =70% by visual angiographic assessment<br><br>          -  Vessel diameter = 4 and = 7 mm<br><br>          -  Patent inflow artery, free from significant lesion (>50%) as confirmed by angiography.<br>             Treatment of the target lesion is acceptable after successful treatment of inflow<br>             iliac and/or common femoral artery lesion. The inflow lesion cannot be treated with a<br>             DCB or a Drug Eluting Stent<br><br>          -  Patent infrapopliteal and popliteal artery, i.e., single vessel runoff or better with<br>             at least one of the three vessels patent (<50% stenosis) to the ankle or foot with no<br>             planned intervention<br><br>        Exclusion Criteria:<br><br>          -  Previously stented target lesion<br><br>          -  Target lesion/ previously treated with drug-coated balloon <12 months prior to<br>             enrollment.<br><br>          -  Use of atherectomy, laser or other debulking devices in the target SFA/PPA vessel<br>             during the index procedure.<br><br>          -  Failure to cross the target lesion with the guide wire<br><br>          -  Presence of a complication following pre-dilation of target lesion, which in the<br>             opinion of the investigator would not allow the procedure to be performed in<br>             accordance with the REACT approach<br><br>          -  Presence of aneurysm in the target vessel.<br><br>          -  Prior on planned major amputation (above the ankle) in the target limb<br><br>          -  Acute ischemia and/or acute thrombosis of the target SFA/PPA vessel prior to<br>             enrollment.<br><br>          -  Perforation of the target vessel as evidenced by extravasation of contrast media prior<br>             to enrollment<br><br>          -  Known hypersensitivity or contraindication to contrast media that, in the opinion of<br>             the investigator, cannot be adequately pre-medicated<br><br>          -  Known hypersensitivity/allergy to Paclitaxel or other components of the<br>             investigational devices and comparator (e.g., nitinol, amorphous silicon carbide,<br>             polymer)<br><br>          -  Known hypersensitivity or contraindication to antiplatelet, anticoagulant,<br>             thrombolytic medications that would be administered during the study<br><br>          -  Subject with uncorrected bleeding disorders<br><br>          -  Subject with renal failure<br><br>          -  Life expectancy less than 12 months due to other comorbidities, that in the<br>             investigators opinion, could limit subject ability to comply with the study required<br>             follow-up visits/procedure and threaten the study scientific integrity<br><br>          -  Pregnant, breast feeding, or plan to become pregnant in the next 12 months.<br><br>          -  Current participation in another investigational drug or device clinical study that<br>             has not completed the primary endpoint at the time of enrollment or that upon<br>             investigator judgment could clinically interferes with the current study endpoints<br>